ATP binding cassette subfamily B member 1 ; Homo sapiens

26 Article(s)
Pub. Year
#Total Relationships
1 33483427 Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor. 2021 Mar 1
2 34158378 Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. 2021 Sep 1 1
3 31262902 Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition. 2019 Jul 2
4 28676669 Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. 2018 Feb 4
5 30497065 Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. 2018 1
6 24364805 Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies. 2014 Feb 3 2
7 22017299 The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. 2012 Jan 2
8 23082557 Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. 2012 Jan 1
9 19478134 Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina. 2009 Aug 2
10 18393290 Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. 2008 Dec 1
11 17591677 Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. 2007 Sep 3
12 16165208 Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women. 2006 Jun-Jul 1
13 17047492 Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. 2006 Nov 1
14 15750390 An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. 2005 Mar 4 4
15 16267764 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. 2005 Dec 1 2
16 15040543 Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. 2004 Feb 6
17 15651752 Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. 2004 Dec 1
18 12902797 The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. 2003 Aug 15 4
19 12917239 Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. 2003 Sep 2
20 11302944 Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. 2001 May 1
21 11468419 HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. 2001 Aug 1 1
22 10820137 Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. 2000 Jun 1
23 11185676 A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. 2000 Dec 1
24 10509562 Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. 1999 Sep 10 4
25 9803961 Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. 1998 Nov 1 2
26 9835508 Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. 1998 Dec 1